Coreo AG — Board/Management Information 2010

Nov 15, 2010

News Details

Corporate | 15 November 2010 11:42

Nanostart subsidiary MagForce Nanotechnologies AG Expands Management Team

Nanostart AG / Key word(s): Miscellaneous

15.11.2010 11:42

• 'important step in the transformation into a commercial company'

• Therapy expected to become available in the first quarter of 2011 at
  leading German cancer centers

• Additional commercialization positions to be filled in the coming weeks

Frankfurt / Berlin - November 15, 2010 - Nanostart subsidiary MagForce
Nanotechnologies AG (FSE:MF6), a leader in the area of nanotechnology-based
cancer treatment, announced today the expansion of its management team. The
new positions will support both the upcoming product launch of the
company's EU approved therapy for the treatment of brain tumors and the
further development of its Nano-Cancer(R) therapy in additional cancer
indications. MagForce expects its Nano-Cancer(R)-therapy will become
available at several leading German cancer centers in the first quarter of
2011.

'Filling these key company positions is an important step in the
transformation of the company from a research and development only business
into a commercial company. Additional hiring for the sales and marketing
team will be completed by the end of the year,' said Dr. Peter Heinrich,
CEO of MagForce. 'I am extremely pleased to welcome Dr. Christoph Rehfuess,
Dr. Dirk Kautz, Mr. Kajo Wiest, and Ms. Stacy Wiedenmann to MagForce.
Furthermore, Dr. Hans Joachim Hutt is currently serving as a medical
consultant. These individuals bring with them the experience and expertise
to support MagForce as we build commercial infrastructures and medical
networks.'

Dr. Christoph Rehfuess joins MagForce as Director of Intellectual Property.
As a qualified European Patent attorney with twelve years of management
experience in the Biotech intellectual property field at MediGene AG, he
will be responsible for patents, trademarks, and technical contracts.

Dr. Dirk Kautz joins MagForce as Director of Business/Corporate Development
and will support the Management Board in strategic planning. Prior to
joining MagForce, he worked for more than 13 years in the medical devices
industry, holding management positions in marketing and corporate
development at, amongst others, Nihon Kohden and Biotronik.

Kajo Wiest joins as Director of Finance & Controlling and brings with him
more than ten years of finance and controlling experience at Jerini AG.
During his time at Jerini, he was responsible for the establishment of
controlling structures as well as supporting the company's IPO and the sale
of its wholly-owned subsidiary JPT, where he served as Finance Manager last
year.

Stacy Wiedenmann joins the company as Director of Investor Relations &
Corporate Communications and brings with her over ten years of experience,
including her experience at Jerini AG where she headed the same areas from
their IPO through their acquisition.

Dr. Hans Joachim Hutt MD, PhD will support the company in the area of
medical affairs. His medical training and over 20 years of experience at
leading pharmaceutical companies, including Boehringer Ingelheim, Sanofi,
Bristol-Myers Squibb, and Sanofi Pasteur MSD, will help MagForce establish
commercial networks and expand its therapeutic applications.

About Nanostart:
Nanostart AG, headquartered in the German financial capital of Frankfurt,
is the world's leading nanotechnology investment company, with portfolio
companies spanning the globe from Silicon Valley to Singapore. The company
provides venture capital financing for nanotechnology companies in various
growth phases with a focus on innovation-driven industries of the future
such as cleantech, life sciences and IT/electronics. Through its subsidiary
and venture capital fund in Singapore, Nanostart is proud to be the
investment partner of the Singaporean government. For further information,
please visit www.nanostart.de.

About MagForce Nanotechnologies:
MagForce Nanotechnologies AG is a world-leading company in the area of
nanotechnology-based cancer treatment. The proprietary procedure which it
has developed, Nano-Cancer(R) therapy, enables the targeted treatment of
solid tumors through the intratumoral release of heat from magnetic
nanoparticles. Its products used in the therapy, NanoTherm(R) and
NanoActivator(R), have received EU-wide regulatory approval as medical
devices for the treatment of brain tumors. For further information, please
visit www.magforce.com.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of
offers to purchase or subscribe to securities. There will be no public
offering of securities of Nanostart AG in conjunction with the existing
listing of its shares in the 'Entry Standard' segment of the regulated
unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This
notice does not constitute a securities prospectus. Neither this notice nor
the information contained within is intended for direct or indirect
distribution within Canada, Australia or Japan.

Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail: presse@nanostart.de

15.11.2010 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---